| Literature DB >> 28011624 |
Joshua N Sampson1, Roni T Falk2, Catherine Schairer2, Steven C Moore2, Barbara J Fuhrman3, Cher M Dallal4, Douglas C Bauer5, Joanne F Dorgan6, Xiao-Ou Shu7, Wei Zheng7, Louise A Brinton2, Mitchell H Gail2, Regina G Ziegler2, Xia Xu8, Robert N Hoover2, Gretchen L Gierach1.
Abstract
Endogenous estradiol and estrone are linked causally to increased risks of breast cancer. In this study, we evaluated multiple competing hypotheses for how metabolism of these parent estrogens may influence risk. Prediagnostic concentrations of estradiol, estrone, and 13 metabolites were measured in 1,298 postmenopausal cases of breast cancer and 1,524 matched controls in four separate patient cohorts. The median time between sample collection and diagnosis was 4.4 to 12.7 years across the cohorts. Estrogen analytes were measured in serum or urine by liquid chromatography-tandem mass spectrometry. Total estrogen levels (summing all 15 estrogens/estrogen metabolites) were associated strongly and positively with breast cancer risk. Normalizing total estrogen levels, we also found that a relative increase in levels of 2-hydroxylation pathway metabolites, or in the ratio of 2-hydroxylation:16-hydroxylation pathway metabolites, were associated inversely with breast cancer risk. These associations varied by total estrogen levels, with the largest risk reductions occurring in women in the highest tertile. With appropriate validation, these findings suggest opportunities for breast cancer prevention by modifying individual estrogen metabolism profiles through either lifestyle alterations or chemopreventive strategies. Cancer Res; 77(4); 918-25. ©2017 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 28011624 PMCID: PMC5313342 DOI: 10.1158/0008-5472.CAN-16-1717
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701